Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP).
Publication/Presentation Date
7-1-2024
Abstract
OBJECTIVE: The impact of pancreaticoduodenectomy on absorption of drugs in the duodenum remains largely unknown. We aim to characterize the pharmacokinetics of apixaban in patients who had previously undergone pancreaticoduodenectomy.
MATERIALS AND METHODS: A single 10-mg dose of apixaban was administered to 4 volunteers who underwent pancreaticoduodenectomy at least 6 months prior. The maximum plasma apixaban concentration (C
RESULTS: In pancreaticoduodenectomy patients, AUC
CONCLUSION: The pharmacokinetic characteristics of apixaban in subjects who had undergone pancreaticoduodenectomy are not significantly different from those of healthy controls. Though the sample size of this study is small, results suggest that no change to apixaban dose regimen is needed in patients who have had a pancreaticoduodenectomy.
Volume
62
Issue
7
First Page
319
Last Page
325
ISSN
0946-1965
Published In/Presented At
Zheng, R., Lam, E., Altshuler, P., Crutcher, M., Lavu, H., Yeo, C. J., Stickle, D., Leiby, B., & Kraft, W. K. (2024). Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP). International journal of clinical pharmacology and therapeutics, 62(7), 319–325. https://doi.org/10.5414/CP204502
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
38660886
Department(s)
Administration and Leadership
Document Type
Article